Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18563919 | 0.92 | TLR7 (0.74) | TLR7 | |
| SCHEMBL18584159 | 0.92 | TLR7 (0.84) | TLR7 | |
| SCHEMBL24007616 | 0.90 | TLR7 (0.84) | TLR7 | |
| SCHEMBL1146189 | 0.87 | TLR7 (0.81) | TLR7 | |
| SCHEMBL18563911 | 0.87 | TLR7 (0.86) | TLR7 | |
| SCHEMBL5459709 | 0.86 | TLR7 (0.75) | TLR7 | |
| SCHEMBL18584158 | 0.85 | TLR7 (0.83) | TLR7 | |
| SCHEMBL24233599 | 0.84 | TLR7 (0.79) | TLR7 | |
| SCHEMBL1146404 | 0.83 | TLR7 (0.82) | TLR7 | |
| SCHEMBL1146536 | 0.82 | TLR7 (0.83) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | EGFR, ERBB3, ERBB2 | TLR7 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.